Ipca Laboratories Limited (IPCALAB) Earnings Call Transcript
November 5, 2026
Earnings Call Speaker Segments
Ladies and gentlemen, good day, and welcome to Ipca Labs Q2 FY '27 Earnings Conference Call hosted by DAM Capital Advisors Limited. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Nitin Agarwal from DAM Capital Advisors. Thank you, and over to you, sir.
Thank you. Good afternoon, everyone, and a very warm welcome to Ipca Labs Q2 F '27 Earnings Call hosted by DAM Capital Advisors Limited. On the call today, we have representing Ipca Labs management, Mr. A.K. Jain, Managing Director; and Mr. Harish Kamat, Corporate Counsel and Company Secretary. I'll hand over the call to Mr. Jain to make the opening comments, and we'll open the floor for questions. Please go ahead, sir.
Thanks, Nitin, and DAM Capital for organizing this call. Today's hearing call and discussions and answer given may include some forward-looking statements based on our current business expectations. This must be viewed in conjunction with the risk that pharmaceutical business face. Our actual future financial performance may differ from what is projected in Brazil. You may take your own judgment based on information given during the call. Our domestic formulation business for Q2 FY '27 has delivered growth of around 14% and it has reached to around INR 1,157 crores as against INR 1,019 crores in Q2 FY '26. Met September 2026, Ipcas ranked remained 16 as per our market share has improved to around 2.11% from as against 2.09% in September '26. Top 6 brands of Ipca fishing them and top 300 brand of the industry. Out of the top out of 16 brands all SP is the top brand of the company, and it has improved its rent to 8 as against 11% in the Q2 FY '26 -- FY '26. Zerodol as the umbrella brand has crossed INR 1,500 crores sales as per IQ in September 2026. It has become the fourth largest brand in IPM. As per IQ, the chronic segment, met September 2006, Ipcas achieved a growth of around against IPM growth of around 17%. As per IP, the acute segment, kaasachieved a growth of around 11%, we are at par with the overall market growth there in acute segment, largely because some of the portfolio like anti-malarials and antibacterials are antimalarials are declining at bacterial is having very marginal growth and even cogen cold is having very low growth. On export formulation business. On a stand-alone basis, IPCA has grown by 32% in Q2 FY '27 to around INR 653 crores as against INR 493 crores in Q2 FY '26. Our promotional branded business in ROW markets has delivered growth of 19% for Q2 FY '27 to around INR 172 crores against INR 145 crores in Q2 FY '26. Generic market, excluding tender on a delivered around 36% growth in Q2 FY '27 to around INR 364 crores against Q2 FY '26. Institutional generics business has delivered growth of around 45% for the quarter. And API has delivered a growth of around 6% for the quarter. solidated Q2 FY '26 business has grown by around 14% to around INR 2,910 crores as against INR 2,557 crores. For Q2 FY '27, we continue to see significant price increase on inputs, logistic cost, shipping cost and even fuel and your energy cost. In spite of all these factors, overall consolidated EBITDA margins have improved to around 22.97% in Q2 FY '27 as against 21.68% in Q2 FY '26. Stand-alone EBITDA margin of IPCA has improved to 26.6% in Q2 FY '27 as against 25.4% in Q2 FY '26. Having given the broad numbers, now I'll request participants to ask questions.
[Operator Instructions] The first question is from the line of Saion Mukherjee from Nomura.
I wanted to check on Zerodol franchise. What's the kind of growth you are seeing? And if you can split between volume and price increase in this? And what's the headroom to grow this franchise? What would be the key drivers? And any competitive pressure that you might be seeing in the market? .
Overall, for, let's say, April to September, if you look at our pain segment has grown by around 14% from 1,000 internal numbers from INR 1,206 from INR 1,065 crores to around INR 1,116 crores. So we are -- is continuously growing at 14% for the first half of the current year. And in fact, in the second quarter -- this quarter of the current financial year, on pain segment, we have grown by around 16% -- the overall pain segment has delivered a number of around INR 628 crores from INR 543 crores. So we have recorded almost around 16% growth. So on a continuous basis, both our portfolio of rheumatoid arthritis and osteoarthritis, which includes drool in all rheumatoid arthritis products that they are continuously performing and continuously growing in the range of around 14% to 15% kind of range. So we have absolutely no concern on that. And in fact, from current INR 1,500 crores of umbrella brand, we are looking similar kind of growth to continue for next 3, 4 years yes.
How much of the growth of, say, 14% to 16% would be the volume led? .
Volume grade growth may be almost around 8% to 9%. And price growth may be around 4%, 4.5%, yes.
And do you expect the volume growth momentum to sustain? .
Yes.
Okay. And sir, 1 other question was on growth and margin guidance, if you can reiterate the numbers, any fresh look you have for FY '27?
In earlier quarters, we have given that earlier quarter, we had given guidance that overall growth guidelines was almost around 12% to 13%, which was revised to 14% to 16%. So that would remain. And consolidated EBITDA margin guidance was from 22% to 23% that will also stand.
And sir, what is your.
We are not revising the guidelines.
Okay. Okay Yes. sir, and what is the medium-term EBITDA expectation, let's say, over the next 2, 3 years, where do you see EBITDA margin consolidated electing.
Every year, we should be improving by almost around 1% to 1.25% of EBITDA on a consolidated basis -- and IPCA EBITDA will go by almost around stand-alone EBITDA.
[Operator Instructions] The next question is from the line of Shashank Kushnakumar from Emkay Global.
So I think this quarter for Unichem QQ, we saw a sharp gross margin uptick -- if you could just share what drove that and whether this is a figure that we can work with going forward as well? And also for Unichem, also, are we sticking with the earlier guidance of top line growth and around 13% margins.
Let's see, Unichem has delivered almost around 20%. 11.3% kind of EBITDA margin in current quarter. I think overall, because of freight increase, the freight was significantly increased in this particular quarter. And freight numbers as almost around INR 30 crores extra has gone in this quarter. If you look at the other expenditure of Unichem, that has moved from INR 142 crores to INR 19 crores. So there is an increase of almost around 47% -- in INR 47 crores in other expenses, out of which almost INR 31.2 crores is only increase in the freight expenses. Also because of significant increase in the increase in overall freight costs and also overall a little increase, let's say, your air shipment has also gone up because of overall time -- the shipping lines are taken to deliver the goods and all that. So some of the consignments was to be sent by air and all. air percentage of overall has gone up almost in this quarter to from 5%, 6% to around 25%. So that has taken almost around INR 30 crores out of freight expenses out of EBITDA that has grown -- and that has resulted in little lower EBITDA margin. Otherwise, let's say that European business has done well Brazil until now they were incurring losses for first 2 quarters of the current financial year that has started delivering now the profit. So in time to come, gradual business will also move up. So if situation normalizes, the margins can move up. But if your freight and all these cost -- energy cost and it remains high, maybe it may remain between 11% to 13% kind of thing. EBITDA margin.
Got it. And the GM that we saw this quarter is sustainable spec, close to 8%.
It may be 1% or 2% here and there, very because input costs are fluctuating too much Yes.
Okay. Sir, and if you could also call out the U.S. portfolio growth, both for IPCA, which is getting booked in Unichem and the Unichem portfolio this quarter?
Overall, let's say, U.S. -- in dollar terms, if you look at overall portfolio growth is almost around 9% -- and IPCA portfolio is, let's say, value growth is almost around 74% in dollar terms. So I think the card portfolio is, I think for the quarter has given almost around $5.8 million of sale. And Unichem's portfolio is almost around has become $38.5 million for the quarter.
The next question is from the line of Rashmi Shetty from Dolat Capital. .
Sir, on the institution 3 billion INR 300 crores for this year, and we have already done INR 236 crores in first you feel that it will be lumpy and in second half sales will be pretty low? Or you are upgrading the guidance for that? .
Institutional business, normally, we don't give any kind of, let's say, very aggressive guidelines because of -- by nature of this business itself, we wish to be very consent this year because of, let's say, when guidelines was given, I think, overall, I think in first quarter, significant amount of shipment, which was to go in last financial year. of non-availability of ships and other businesses got shifted in the first quarter of the current year, that shipment was almost around INR 25 crores -- but in second quarter also, we have grown good in this financial year -- and the trend would continue. But we don't expect this kind of growth.
Okay. So as of now, we should maintain that INR 300 crores number for the INR 300 crores Full year. .
It will certainly exceed because what this INR 25 crores was never taken into account on guideline. So maybe it may become INR 325 , INR 330, 340. But Overall, we don't expect this business to grow significantly. It may come down also next year here and there.
Got it. Got it, sir. And sir, on the branded business front, we still maintain that 15% growth. So in Generics and banked business, we should expect a little soft quarter in H2, right, to achieve the guidance?
Business is going good on generics. We are delivering good growth overall. And branded business, let's say, overall in the first half of the current year has given growth of almost around 22%, except 1 particular geography where West Asia shipment not happening in time has given some kind of decline in that business a little bit by 3%. But overall, all other market has grown very well, in fact. So we maintain our guidelines of 15% to 16% growth overall India .
Okay. And sir, on the bookkeeping question. On the interest cost part, you all have repaid some debt right on the long-term borrowing and the interest cost was still high in quarter 2. If you can explain related to that? And how should we see the run rate in quarter 3 and quarter 4.
Our interest cost in the quarter 2 has also come down. It's not gone up because last year, we have paid our entire foreign currency debt, which was outstanding and booked because we were carrying the cash in so we before this -- around the time then the rupee depreciation started, we thought that let us pay every -- all dollar loans in books. So right now, we have only very small borrowing of around INR 155 crores or so on rupee term loan, which probably at the year-end will grow by around INR 70 crores, INR 75 crores. I think that's the balance going to remain at this and practically, we are a debt-free company because we are getting almost around INR 700 crores cash in books and let or Harlan. That debt also we are not doing because that debt is contracted at very low rate compared to the current market rate what we are realizing on deploying money in mutual funds and all. So we are not prepaying that debt.
Correct. I understood. What I meant was that this INR 12 crores run rate, which we have done in the last 2 quarters, this number should decline in H2, right, because of the debt.
Yes, it will decline Yes, it would decline, yes.
[Operator Instructions] The next question is from the line of Nitin Agarwal from DAM Capital Advisors.
Just a couple of questions from my side. Sir, on the -- if you can give us a little bit more color on how the U.K. and the Europe business is U.K., Europe and the Australia business have this quarter in the first half?
Yes, I'll give the number here. Overall, generics wise, if you look at in Q2, European business has grown by around 23%, Australia and New Zealand has grown by around 24%. U.S. has grown by 31%. Canada has grown by 5% South African business has grown by 46%. Overall, so most businesses in Gatwick has done well Yes.
And for, U.K., we had some issues here every now and then. So those business has now stabilized for the U.K.? .
U.K. as my portfolio is growing. Last financial year, we were facing a lot of problem in because of, let's say, our under kind of portfolio was just very old products, maybe genesis 15, 20 years old, and those products were selling below cost in the market. So last year in Europe, in U.K., we have U.K. portfolio, we have suffered in the overall I think in the whole of the year, maybe around 2.5 million kind of loss in U.K. But because of that kind of scenario, there are lots of disturbance in U.K. market today that a lot of products are going in short supplies and all. And prices are returning back because situation of selling product at lower price cannot continue for long. So that has changed in the European this U.K. subsidiary has also delivered profit in this year and U.K. overall business is moving up now.
And sir, on our subsidiaries, you can give us an update on how the various subsidiaries done? .
Let's say, except 1 subsidiary, which is disclosed all subsidiaries have done well, and they are all in profits here. Some a little more time because there are good order positions on their API side. And so maybe I think by next financial year, the things will start improving there.
[Operator Instructions] As there are no further questions from the participants, I now hand the conference over to management for closing comments. Thank you, and over to yousir.
Yes. Thank you, Madam. Having answered all the questions, I think we can close this on car. Thank you, everyone, for participating in this phone call.
Thank you. sir. On behalf of DAM Capital Advisors Limited, that concludes this conference call. Thank you all for joining us, and you may now disconnect your lines. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ipca Laboratories Limited transcript - plus 261,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Ipca Laboratories Limited earnings transcripts and 261,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $145 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.